NVS
Price
$115.92
Change
+$2.43 (+2.14%)
Updated
Aug 7, 04:47 PM (EDT)
Capitalization
197.93B
82 days until earnings call
RHHBF
Price
$319.50
Change
-$12.89 (-3.88%)
Updated
Aug 6 closing price
Capitalization
250.69B
Interact to see
Advertisement

NVS vs RHHBF

Header iconNVS vs RHHBF Comparison
Open Charts NVS vs RHHBFBanner chart's image
Novartis AG
Price$115.92
Change+$2.43 (+2.14%)
Volume$1.7K
Capitalization197.93B
Roche Holding
Price$319.50
Change-$12.89 (-3.88%)
Volume$2
Capitalization250.69B
NVS vs RHHBF Comparison Chart in %
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. RHHBF commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and RHHBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (NVS: $113.50 vs. RHHBF: $319.50)
Brand notoriety: NVS and RHHBF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 125% vs. RHHBF: 3%
Market capitalization -- NVS: $197.93B vs. RHHBF: $250.69B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. RHHBF’s [@Pharmaceuticals: Major] market capitalization is $250.69B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileRHHBF’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • RHHBF’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while RHHBF’s TA Score has 2 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 6 bearish.
  • RHHBF’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, NVS is a better buy in the short-term than RHHBF.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а -2.68% price change this week, while RHHBF (@Pharmaceuticals: Major) price change was -5.68% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.63%. For the same industry, the average monthly price growth was +7.79%, and the average quarterly price growth was +14.77%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.63% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBF($251B) has a higher market cap than NVS($198B). NVS has higher P/E ratio than RHHBF: NVS (23.38) vs RHHBF (21.19). NVS YTD gains are higher at: 20.837 vs. RHHBF (6.082). RHHBF (19.1B) and NVS (18.3B) have comparable annual earnings (EBITDA) . NVS has more cash in the bank: 14B vs. RHHBF (7.51B). RHHBF (25.4B) and NVS (26.3B) have identical debt. RHHBF has higher revenues than NVS: RHHBF (60B) vs NVS (46.7B).
NVSRHHBFNVS / RHHBF
Capitalization198B251B79%
EBITDA18.3B19.1B96%
Gain YTD20.8376.082343%
P/E Ratio23.3821.19110%
Revenue46.7B60B78%
Total Cash14B7.51B186%
Total Debt26.3B25.4B104%
FUNDAMENTALS RATINGS
NVS vs RHHBF: Fundamental Ratings
NVS
RHHBF
OUTLOOK RATING
1..100
5760
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
20100
SMR RATING
1..100
2998
PRICE GROWTH RATING
1..100
5258
P/E GROWTH RATING
1..100
8346
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (16) in the Pharmaceuticals Major industry is in the same range as RHHBF (16) in the null industry. This means that NVS’s stock grew similarly to RHHBF’s over the last 12 months.

NVS's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBF (100) in the null industry. This means that NVS’s stock grew significantly faster than RHHBF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBF (98) in the null industry. This means that NVS’s stock grew significantly faster than RHHBF’s over the last 12 months.

NVS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as RHHBF (58) in the null industry. This means that NVS’s stock grew similarly to RHHBF’s over the last 12 months.

RHHBF's P/E Growth Rating (46) in the null industry is somewhat better than the same rating for NVS (83) in the Pharmaceuticals Major industry. This means that RHHBF’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHBF
RSI
ODDS (%)
Bullish Trend 2 days ago
44%
Bearish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
62%
Momentum
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
38%
Bearish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
40%
Bearish Trend 2 days ago
61%
Advances
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 15 days ago
60%
Declines
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
46%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bearish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GIGM1.480.03
+2.39%
GigaMedia Limited
CNOB22.870.07
+0.31%
ConnectOne Bancorp
ESHA11.10N/A
N/A
ESH Acquisition Corp
TS35.33-0.45
-1.26%
Tenaris S A
SBSW8.75-0.21
-2.34%
Sibanye-Stillwater

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-3.59%
GSK - NVS
67%
Closely correlated
-1.53%
AZN - NVS
61%
Loosely correlated
-1.18%
PFE - NVS
57%
Loosely correlated
-3.31%
JNJ - NVS
54%
Loosely correlated
-0.09%
SNY - NVS
49%
Loosely correlated
-3.47%
More

RHHBF and

Correlation & Price change

A.I.dvisor tells us that RHHBF and RHHBY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RHHBF and RHHBY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBF
1D Price
Change %
RHHBF100%
-3.88%
RHHBY - RHHBF
32%
Poorly correlated
-2.69%
RHHVF - RHHBF
25%
Poorly correlated
-2.89%
NVS - RHHBF
20%
Poorly correlated
-3.59%
JNJ - RHHBF
16%
Poorly correlated
-0.09%
ABBV - RHHBF
16%
Poorly correlated
-1.13%
More